• Megan E Feeney, Anica C Law, Allan J Walkey, and Nicholas A Bosch.
• Department of Pharmacy, Boston Medical Center, Boston, MA.
• Crit. Care Med. 2024 Jul 1; 52 (7): e365e375e365-e375.

ObjectivesTo describe practice patterns surrounding the use of medications to treat opioid use disorder (MOUD) in critically ill patients.DesignRetrospective, multicenter, observational study using the Premier AI Healthcare Database.SettingThe study was conducted in U.S. ICUs.PatientsAdult (≥ 18 yr old) patients with a history of opioid use disorder (OUD) admitted to an ICU between 2016 and 2020.InterventionsNone.Measurements And Main ResultsOf 108,189 ICU patients (658 hospitals) with a history of OUD, 20,508 patients (19.0%) received MOUD. Of patients receiving MOUD, 13,745 (67.0%) received methadone, 2,950 (14.4%) received buprenorphine, and 4,227 (20.6%) received buprenorphine/naloxone. MOUD use occurred in 37.9% of patients who received invasive mechanical ventilation. The median day of MOUD initiation was hospital day 2 (interquartile range [IQR] 1-3) and the median duration of MOUD use was 4 days (IQR 2-8). MOUD use per hospital was highly variable (median 16.0%; IQR 10-24; range, 0-70.0%); admitting hospital explained 8.9% of variation in MOUD use. A primary admitting diagnosis of unintentional poisoning (aOR 0.41; 95% CI, 0.38-0.45), presence of an additional substance use disorder (aOR 0.66; 95% CI, 0.64-0.68), and factors indicating greater severity of illness were associated with reduced odds of receiving MOUD in the ICU.ConclusionsIn a large multicenter, retrospective study, there was large variation in the use of MOUD among ICU patients with a history of OUD. These results inform future studies seeking to optimize the approach to MOUD use during critical illness.Copyright © 2024 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

39 keywords...

hide…